FAILED TRIAL: Phase 3 LITESPARK-012 Trial of KEYTRUDA, LENVIMA, and WELIREG did not meet the dual primary endpoints of PFS and OS in 1L RCC April 28, 2026
Darlifarnib + Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell RCC Previously Treated With Cabozantinib April 21, 2026
WELIREG + LENVIMA Reduced the Risk of Disease Progression or Death by 30% vs Cabozantinib in Certain Previously Treated Patients With Advanced RCC March 3, 2026
Adjuvant KEYTRUDA + WELIREG Reduced the Risk of Disease Recurrence or Death by 28% vs KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage RCC March 3, 2026
Tempest plans to prioritize development of clinical-stage dual-targeting CD19/BCMA CAR-T program, TPST-2003 February 17, 2026
KEYTRUDA + WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell RCC Following Nephrectomy November 4, 2025
WELIREG + LENVIMA Met Primary Endpoint of PFS in Certain Previously Treated Patients With Advanced RCC November 4, 2025
Significant and Sustained Survival Benefit announced from Ph 2 (Actuate-1801 Part 3B) trial of elraglusib + GnP combo in 1L metastatic pancreatic adenocarcinoma July 1, 2025
Sandoz enters global collaboration license agreement with Henlius to commercialize ipilimumab in multiple indications May 6, 2025
FRUSICA-2 Ph 2/3 Study of Sintilimab and Fruquintinib Combination Met Primary Endpoint in Advanced RCC in China March 26, 2025
EMA approves WELIREG® (belzutifan) for advanced clear cell RCC that progressed following a PD(L)-1 inhibitor and at least two VEGF therapies February 25, 2025
Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of VHL Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced RCC December 18, 2024
FDA Regenerative Medicine Advanced Therapy (RMAT) Designation granted to ALLO-316 for Adult Patients with Advanced or Metastatic RCC November 5, 2024
First Patient Dosed in Clinical Collaboration Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC October 29, 2024
Exelixis and Merck to Evaluate Zanzalintinib in Combination With KEYTRUDA in Head and Neck Cancer and in Combination With WELIREG in RCC October 15, 2024
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in RCC October 8, 2024
Ph 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study Announced September 24, 2024
GI Innovation Announces New Clinical Trial Collaboration and Supply Agreement to Evaluate GI-102 + KEYTRUDA in Patients with IO-Resistant HCC, Melanoma, and RCC September 3, 2024
FAILED TRIAL: Ph 3 TiNivo-2 didn’t meet primary endpoint from rechallenging RCC patients with immunotherapy after receiving ICI beyond progression on previous ICIs July 23, 2024
